Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2015

View Archived Issues

First-in-human results presented for LY-3023414

CD-133-targeted oncolytic adenovirus therapy shows promising preclinical results

Grant supports Adenovir's development of second-generation drug for epidemic keratoconjunctivitis

Medical Developments agrees to term sheet for European distribution of Penthrox

Bavarian Nordic confirms option exercise by U.S. Government for Filovirus vaccine

Almirall returns Kappaproct rights to InDex

New ultra-long-acting insulin analogue with improved PK/PD profile

Threshold Pharmaceuticals begins phase II study of TH-4000 in NSCLC

Novartis reports phase I results for INC-280 plus erlotinib

Nuclea Biotechnologies partners with Aelan Cell Technologies in epigenetics field

CytRx's new LADR technology platform expected to expand oncology pipeline

The Dana-Farber Cancer Institute discloses kinase inhibitors

First-in-human clear images of glioblastoma patients using [18F]AA-7

Roche provides initial update from phase IIb trial of sembragiline in Alzheimer's disease

Clovis Oncology begins rolling NDA submission for rociletinib

ALS groups fund two phase II studies focused on biomarkers

Preclinical and first-in-human data of BI-655064 as a CD40 inhibitor

Spiolto Respimat approved in first European countries for COPD

Yervoy receives approval for unresectable malignant melanoma in Japan

University of Tsukuba patent describes orexin OX2 receptor agonists

Roche and Chugai present BTK inhibitors

P2X4 negative modulators for pain in early development at Sunovion

Ajinomoto divulges AJS-1669 for type 2 diabetes

FDA approves Tuxarin ER

FDA grants approval to Orkambi for cystic fibrosis

Lilly's GLP-1 receptor agonist Trulicity Ateos approved in Japan

Boehringer Ingelheim's Ofev receives approval for IPF in Japan

Harvoni approved in Japan for genotype 1 HCV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...